CymaBay Therapeutics Inc.

NAS: CBAY

GO
/marketstate/country/us

Market open

 --Real time quotes

Oct 15, 2019, 11:53 a.m.

/zigman2/quotes/201917619/composite

$

4.72

Change

+0.31 +7.03%

Volume

Volume 328,303

Real time quotes

/zigman2/quotes/201917619/composite

Previous close

$ 4.41

$ 4.72

Change

+0.31 +7.03%

Day low

Day high

$4.42

$4.75

Open

52 week low

52 week high

$4.23

$14.00

Open

Insider Actions for CymaBay Therapeutics Inc.

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/23/2019 Sujal Shah
Chief Executive Officer; Director
3,100   Acquisition at $5.55 per share. 17,205
09/20/2019 Sujal Shah
Chief Executive Officer; Director
1,900   Acquisition at $5.5 per share. 10,450
02/07/2019 Carl Samuel Goldfischer
Director
11,675   Disposition at $9.02 per share. 105,308
02/07/2019 Carl Samuel Goldfischer
Director
9,340   Derivative/Non-derivative trans. at $5.5 per share. 51,370
02/07/2019 Carl Samuel Goldfischer
Director
2,335   Derivative/Non-derivative trans. at $5 per share. 11,675
12/21/2018 Sujal Shah
Chief Executive Officer; Director
10,000   Acquisition at $6.54 per share. 65,400
12/18/2018 Abingworth LLP
Director
53,492   Disposition at $7.43 per share. 397,445
12/17/2018 Abingworth LLP
Director
88,889   Disposition at $8.17 per share. 726,223
10/15/2018 Sujal Shah
Chief Executive Officer; Director
5,000   Acquisition at $9.9 per share. 49,500
08/29/2018 Daniel Menold
Vice President, Finance
5,000   Disposition at $13 per share. 65,000
08/29/2018 Daniel Menold
Vice President, Finance
5,000   Derivative/Non-derivative trans. at $5 per share. 25,000
07/27/2018 Sujal Shah
Chief Executive Officer; Director
5,000   Acquisition at $10.9 per share. 54,500
05/11/2018 Sujal Shah
Chief Executive Officer; Director
5,000   Acquisition at $10.65 per share. 53,250

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
2 Purchases
0 Sales
5,000
0
Last 6 months
2 Purchases
0 Sales
5,000
0
Last 12 months
5 Purchases
3 Sales
26,675
154,056

Officers and Executives

Mr. Sujal Shah
President, Chief Executive Officer & Director
Dr. Charles A. McWherter
Chief Scientific Officer & Senior Vice President
Ms. Janet Dorling
Chief Commercial Officer
Dr. Patricia Rohane
Vice President-Clinical Development
Ms. Klara A. Dickinson-Eason
Chief Regulatory & Compliance Officer
Mr. Daniel Menold
Vice President-Finance
Mr. Patrick J. O'Mara
Senior Vice President-Business Development
Mr. Paul T. Quinlan
Secretary & General Counsel
Dr. Robert James Wills
Chairman
Ms. Caroline M. Loewy
Independent Director
Dr. Robert F. G. Booth
Independent Director
Dr. Evan A. Stein
Independent Director
Mr. Robert J. Weiland
Independent Director
Mr. Paul F. Truex
Independent Director
Mr. Konrad Hans von Emster
Independent Director
Dr. Carl Samuel Goldfischer
Independent Director
Link to MarketWatch's Slice.